- $41.39m
- $148.50m
- $458.51m
Accuray Inc reports results for the quarter ended in September - Earnings Summary
Brief: Accuray Reports Fiscal Q1 2023 Financial Results
Brief: Accuray Announces Tomo C Registration Submission To China's National Medical Products Administration
Accuray Inc expected to post a loss of 2 cents a share - Earnings Preview
Brief: New Reimbursement Approved By The Japanese Ministry Of Health, Labor And Welfare For The Accuray Cyberknife® System To Treat Trigeminal Neuralgia, A Condition Often Causing Severe Facial Pain
Brief: Accuray Partners With Swiss-Based Genolier Innovation Hub To Bring Medical And Technological Advances To Patients Faster
Brief: Accuray Reports Q4 Loss Per Share $0.04
Accuray Inc reports results for the quarter ended in June - Earnings Summary
Accuray Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Accuray Cyberknife System Real World Data And Clinical Studies Show Benefits In Treatment Of Neurological Indications
Brief: Accuray And Limbus AI Inc Partner To Leverage Limbus' Innovative AI-Driven Technology
Brief: Accuray Announces Suzanne Winter, President, Promoted To President And CEO
Brief: Accuray Reports Q3 Loss Per Share $0.01
Accuray Inc reports results for the quarter ended in March - Earnings Summary
Accuray Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Accuray Tomotherapy® Helical Radiotherapy System Helps Preserve Breast Cancer Patients' Long-Term Heart And Lung Functionality
Brief: Accuray Reports Fiscal 2022 Second Quarter Financial Results
Accuray Inc reports results for the quarter ended in December - Earnings Summary
Accuray Inc expected to post breakeven results a share - Earnings Preview